ABC | Volume 112, Nº5, Maio 2019

Artigo Original Warpechowski Neto et al Readmissão hospitalar – dispositivos implantáveis Arq Bras Cardiol. 2019; 112(5):491-498 1. MossAJ,ZarebaW,HallWJ,KleinH,WilberDJ,CannomDS,etal;Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83. 2. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539-49. 3. Sosa EA, de Paola AA, Martinelli M, Costa R, Pimenta J, Lorga AM, et al. [Recommendations of the Department of Arrhythmia and Clinical Electrophysiology (DAEC) of the Brazilian Cardiology Society on indications for permanent pacemaker implantation, choice of stimulation mode, and indications for automatic cardioverter-defibrillator implantation]. Arq Bras Cardiol. 1995;64(6):579-83. 4. Udo EO, Zuithoff NP, vanHemel NM, de Cock CC, Hendriks T, Doevendans PA, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. 2012;9(5):728-35. 5. Pakarinen S, Oikarinen L, Toivonen L. Short-term implantation-related complications of cardiac rhythm management device therapy: a retrospective single-centre 1-year survey. Europace. 2010;12(1):103-8. 6. van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L. Implantation-relatedcomplicationsof implantablecardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J AmColl Cardiol. 2011;58(10):995-1000. 7. Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, et al; Heart Rhythm Society; European Heart Rhythm Association; American College of Cardiology; American Heart Association; European Society of Cardiology; Heart Failure Association of ESC; Heart Failure Society of America. HRS/EHRA expert consensus on themonitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Heart Rhythm. 2008;5(6):907-25. 8. Lee DS, Krahn AD, Healey JS, Birnie D, Crystal E, Dorian P JS, et al; Investigators of theOntario ICDDatabase. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol. 2010;55(8):774-82. 9. Ghani A, Delnoy PP, Ramdat Misier AR, Smit JJ, Adiyaman A, Ottervanger JP, etal. Incidenceof leaddislodgement,malfunctionandperforationduringthe first year following device implantation. Neth Heart. J 2014;22(6):286-91. 10. Ezzat VA, Lee V, Ahsan S, Chow AW, Segal O, Rowland E, et al. A systematic review of ICD complications in randomised controlled trials versus registries: is our ‘real-world’ data an underestimation? Open Heart. 2015;2(1):e000198. 11. Tobin K, Stewart J,Westveer D, FruminH. Acute complications of permanent pacemaker implantation: their financial implication and relation to volume and operator experience. Am J Cardiol. 2000;85(6):774-6. 12. Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD, et al. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol. 2006;47(12):2493-7. 13. Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N, et al; PEOPLE Study Group. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation. 2007;116(12):1349-55. 14. Tajstra M, Gadula-Gacek E, Kurek A, Adamowicz-Czoch E, Olszowski D, Ostr ę gaM, et al. Complications in recipients of cardioverter-defibrillator or cardiac resynchronization therapy: Insights fromSilesianCenter Defibrillator registry. Cardiol J. 2017;24(5):515-22. 15. Da Costa A, Kirkorian G, Cucherat M, Delahaye F, Chevalier P, Cerisier A, et al. Antibiotic prophylaxis for permanent pacemaker implantation: a meta- analysis. Circulation. 1998;97(18):1796-801. 16. deOliveira JC, Martinelli M, Nishioka SA, Varejão T, Uipe D, Pedrosa AA, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2(1):29-34. 17. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al; BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368(22):2084-93. 18. Cheng A, Nazarian S, Brinker JA, Tompkins C, Spragg DD, Leng CT, et al. Continuation of warfarin during pacemaker or implantable cardioverter- defibrillator implantation: a randomized clinical trial. Heart Rhythm. 2011;8(4):536-40. 19. Young JB, AbrahamWT, Smith AL, Leon AR, Lieberman R, Wilkoff B, et al; Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: theMIRACLE ICD Trial. JAMA. 2003;289(20):2685-94. 20. Rocha EA, Pereira FT, Abreu JS, Lima JW, Monteiro Mde P, Rocha Neto AC, et al. Development and validation of predictive models of cardiac mortality and transplantation in resynchronization therapy. Arq Bras Cardiol. 2015;105(4):399-409. 21. Silva KR, Albertini CM, Crevelari ES, Carvalho EI, Fiorelli AI, Martinelli M Filho, et al. Complications after surgical procedures in patients with cardiac implantable electronic devices: results of a prospective registry. Arq Bras Cardiol. 2016;107(3):245-56. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 498